220 related articles for article (PubMed ID: 19883882)
81. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period.
Tran DH; Wong GT; Chee YE; Irwin MG
Expert Opin Biol Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24219367
[TBL] [Abstract][Full Text] [Related]
82. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
Hollingsworth K; Romney MC; Crawford A; McAna J
Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
[TBL] [Abstract][Full Text] [Related]
83. The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?
Fishbane S; Nissenson AR
Kidney Int; 2007 Oct; 72(7):806-13. PubMed ID: 17597700
[TBL] [Abstract][Full Text] [Related]
84. Zinc deficiency anaemia in haemodialysis patients: Often overlooked but a treatable cause of anaemia.
Taki Y; Imai N; Shibagaki Y
Nephrology (Carlton); 2017 Dec; 22(12):1037-1038. PubMed ID: 29145703
[No Abstract] [Full Text] [Related]
85. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
[TBL] [Abstract][Full Text] [Related]
86. Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis.
Wetmore JB; Li S; Yan H; Xu H; Peng Y; Sinsakul MV; Liu J; Gilbertson DT
PLoS One; 2018; 13(9):e0203767. PubMed ID: 30256836
[TBL] [Abstract][Full Text] [Related]
87. Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: what is the evidence?
Roger SD
Int J Clin Pract; 2008 Sep; 62(9):1413-22. PubMed ID: 18793377
[TBL] [Abstract][Full Text] [Related]
88. Anemia management in chronic kidney disease.
Fishbane S; Nissenson AR
Kidney Int Suppl; 2010 Aug; (117):S3-9. PubMed ID: 20671741
[TBL] [Abstract][Full Text] [Related]
89. Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case-control study.
René É; Lazrak HH; Laurin LP; Elftouh N; Vallée M; Lafrance JP
Nephrol Dial Transplant; 2017 Jun; 32(6):1047-1052. PubMed ID: 27448671
[TBL] [Abstract][Full Text] [Related]
90. Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis.
Mesgarpour B; Heidinger BH; Schwameis M; Kienbacher C; Walsh C; Schmitz S; Herkner H
Intensive Care Med; 2013 Nov; 39(11):1896-908. PubMed ID: 23928897
[TBL] [Abstract][Full Text] [Related]
91. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia.
Leaf DE; Goldfarb DS
Kidney Int; 2009 Jan; 75(1):15-24. PubMed ID: 18813284
[TBL] [Abstract][Full Text] [Related]
92. Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis.
Winkelmayer WC
Semin Dial; 2010; 23(5):486-91. PubMed ID: 21069924
[TBL] [Abstract][Full Text] [Related]
93. Is there a difficulty in maintaining haemoglobin target levels in pre-dialysis patients treated with erythropoiesis-stimulating agents?
Santacana-Juncosa E; Padullés-Zamora N; Padullés-Zamora A; Comas-Sugrañes D; Santulario-Verdú L; Sanmartí-Martínez N; Martínez-Castelao A
Nefrologia; 2014; 34(2):263-4. PubMed ID: 24658202
[No Abstract] [Full Text] [Related]
94. Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer.
Bennett CL; Becker PS; Kraut EH; Samaras AT; West DP
Semin Dial; 2009; 22(1):1-4. PubMed ID: 19175532
[TBL] [Abstract][Full Text] [Related]
95. Emerging drugs for the treatment of kidney disease-induced anemia.
Malyszko J; Malyszko JS
Expert Opin Emerg Drugs; 2016 Sep; 21(3):315-30. PubMed ID: 27537859
[TBL] [Abstract][Full Text] [Related]
96. Anemia management in cancer patients with chronic kidney disease.
Latcha S
Semin Dial; 2019 Nov; 32(6):513-519. PubMed ID: 31596520
[TBL] [Abstract][Full Text] [Related]
97. Management of anemia by convective treatments.
Locatelli F; Manzoni C; Del Vecchio L; Di Filippo S; Pontoriero G; Cavalli A
Contrib Nephrol; 2011; 168():162-172. PubMed ID: 20938137
[TBL] [Abstract][Full Text] [Related]
98. Activin receptor ligand traps in chronic kidney disease.
Jelkmann W
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
[TBL] [Abstract][Full Text] [Related]
99. Pharmacovigilance in practice: erythropoiesis-stimulating agents.
Hedenus M; Ludwig H; Henry DH; Gasal E
Cancer Med; 2014 Oct; 3(5):1416-29. PubMed ID: 24890561
[TBL] [Abstract][Full Text] [Related]
100. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
J Cancer Res Clin Oncol; 2012 Feb; 138(2):179-87. PubMed ID: 21972052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
